The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COSTEM 2023 | Glofitamab in R/R DLBCL: updated safety and efficacy data
Carmelo Carlo-Stella, MD, PhD, Humanitas Clinical and Research Center, Rozzano, Italy, discusses the mechanism of action of the CD3xCD20 bispecific antibody glofitamab, and further highlights updated safety and efficacy data with the use of this agent in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Prof. Carlo-Stella comments on the promising response rates observed with glofitamab in patients with heavily pretreated disease, and further discusses the toxicity profile of this agent. This interview took place at The 8th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2023), held in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
